DNMT1 and neoplasm: Preclinical studies suggest that DNMT inhibitors can enhance tumor immunogenicity by upregulating cancer-testis antigens and major histocompatibility complex (MHC) molecules, as well as activating interferon signaling pathways (Chen et al., 2020).